A researcher can originate a study while its sponsor, investigators, supplier and funders have distinct responsibilities. The protocol and regulatory arrangement identify who does what.
Investigator-initiated describes the origin of a study, not its phase, evidence strength or authorization. Under U.S. drug-investigation rules, a sponsor initiates and takes responsibility for the investigation; an investigator conducts it. An individual sponsor-investigator has both sets of responsibilities. An academic institution can also sponsor a study. Product supply or funding alone should not be used to infer the regulatory sponsor. The proposed protocol determines whether an IND or another applicable arrangement is needed.
Shares Investigational New Drug application, Expanded access (compassionate use), Trial protocol and statistical analysis plan, Clinical trial.
Shares Investigational New Drug application, Expanded access (compassionate use), Off-label, Clinical trial.
Shares Trial protocol and statistical analysis plan, Clinical trial.
Shares Trial protocol and statistical analysis plan, Clinical trial.
Shares Trial protocol and statistical analysis plan, Clinical trial.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/